M Herling
Overview
Explore the profile of M Herling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling C, et al.
Blood
. 2022 Jun;
140(20):2113-2126.
PMID: 35704690
The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell...
2.
Grau S, Herling M, Mauch C, Galldiks N, Golla H, Schlamann M, et al.
Chirurg
. 2021 Jan;
92(3):200-209.
PMID: 33502584
The incidence, treatment and prognosis of patients with brain metastases have substantially changed during the last decades. While the survival time after diagnosis of cerebral metastases was on average a ...
3.
Oberbeck S, Schrader A, Warner K, Jungherz D, Crispatzu G, von Jan J, et al.
Blood
. 2020 Dec;
136(24):2786-2802.
PMID: 33301031
T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are insufficiently characterized. Constitutive activation of the T-cell leukemia 1A (TCL1A) oncogene...
4.
Putzer S, Varghese L, von Jan J, Braun T, Giri A, Mayer P, et al.
Leukemia
. 2020 Oct;
35(1):293.
PMID: 33097839
No abstract available.
5.
Putzer S, Varghese L, von Jan J, Braun T, Giri A, Mayer P, et al.
Leukemia
. 2020 Feb;
34(9):2513-2518.
PMID: 32099034
No abstract available.
6.
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Putzer S, von Jan J, et al.
Nat Commun
. 2018 Feb;
9(1):697.
PMID: 29449575
T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), and nucleotide sequences...
7.
Andersson E, Putzer S, Yadav B, Dufva O, Khan S, He L, et al.
Leukemia
. 2017 Aug;
32(3):774-787.
PMID: 28804127
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells with an urgent need for rationally designed therapies to address its notoriously chemo-refractory behavior. The median survival...
8.
Coppe A, Andersson E, Binatti A, Gasparini V, Clemente M, Herling M, et al.
Leukemia
. 2017 Feb;
31(5):1243-1246.
PMID: 28167832
No abstract available.
9.
Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider J, Babu V, et al.
Leukemia
. 2016 Oct;
31(5):1177-1186.
PMID: 27773933
Treatment resistance becomes a challenge at some point in the course of most patients with chronic lymphocytic leukemia (CLL). This applies to fludarabine-based regimens, and is also an increasing concern...
10.
Spinner S, Crispatzu G, Yi J, Munkhbaatar E, Mayer P, Hockendorf U, et al.
Leukemia
. 2016 Apr;
30(7):1520-30.
PMID: 27055871
T lymphocyte non-Hodgkin's lymphoma (T-NHL) represents an aggressive and largely therapy-resistant subtype of lymphoid malignancies. As deregulated apoptosis is a frequent hallmark of lymphomagenesis, we analyzed gene expression profiles and...